EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Phase 1 Study Evaluating the Pharmacokinetics, Dose Proportionality, Bioavailability, and Tolerability of Subcutaneous Levothyroxine Sodium ( XP ‐8121)

Richard Fitch iD, Diane R Mould iD, Valentina Conoscenti iD, Robbie Huang, Dawn Harper iD

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70244 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Richard Fitch und 4 weiteren Autor:innen. Beteiligte Einrichtung: Xeris Pharmaceuticals, Inc., Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Thyroxine, Hypothyroidism. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Xeris Pharmaceuticals Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Levothyroxine sodium has been the cornerstone of hypothyroidism management worldwide, with daily oral administration (PO) recognized as standard of care. Oral administration of levothyroxine, however, poses challenges due to variability in pharmacokinetics (PK), influenced by factors such as gastrointestinal absorption, food/drug interactions, and patient adherence. XP‐8121 (levothyroxine for subcutaneous administration) is a ready‐to‐use, subcutaneous (SC) injection formulation of levothyroxine in Phase 3 development. This Phase 1, single‐center, 2‐part study aimed to characterize the PK and dose proportionality of XP‐8121 SC compared to 600 μg oral Ievothyroxine in healthy adults. Additionally, the study evaluated the safety and tolerability of XP‐8121 and incorporated population pharmacokinetic (PPK) modeling to support future development. Part 1 was a randomized, open‐label, crossover, fixed‐sequence study ( n = 30). Dose linearity was evaluated by escalating XP‐8121 SC doses up to 1200 μg. Part 2 was an open‐label, single‐period study ( n = 30) evaluating PK characteristics of a single dose of XP‐8121 SC (1500 μg), potential clinical exposure range, and dose proportionality. After oral levothyroxine administration, baseline‐adjusted levothyroxine concentration increased rapidly in plasma ( T max median: 3.1 h); absorption for all XP‐8121 SC doses was slower compared to 600 μg oral levothyroxine, and levels remained elevated for 4–5 days before decreasing. Dose proportionality was confirmed, and safety results were similar between all groups. PPK analysis results suggested that weekly doses of XP‐8121 SC at four times the daily oral levothyroxine dose provide similar exposure at steady state (AUC ss ). Overall, these data for XP‐8121 provide adequate predictive performance to inform future phase 2 studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThyroxineHypothyroidismHumansAdultMaleFemaleBiological AvailabilityMiddle AgedInjections, SubcutaneousCross-Over StudiesYoung AdultAdministration, OralDose-Response Relationship, DrugHealthy VolunteersAdolescent

Stichwörter der Autor:innen

TSHXP‐8121hypothyroidismlevothyroxineonce‐weeklypharmacokineticssubcutaneous

Substanzen

Thyroxine

Autor:innen und Institutionen

  • Xeris Pharmaceuticals, Inc., Chicago, Illinois, USA.
  • Projections Research, Inc., Phoenixville, Pennsylvania, USA.

ORCID-Profile: Richard Fitch, Diane R Mould, Valentina Conoscenti, Dawn Harper

Förderung

  • Xeris Pharmaceuticals Inc

Zitieren

APA

Fitch, R., Mould, D. R., Conoscenti, V., Huang, R., & Harper, D. (2025). Phase 1 Study Evaluating the Pharmacokinetics, Dose Proportionality, Bioavailability, and Tolerability of Subcutaneous Levothyroxine Sodium ( XP ‐8121). Clinical and Translational Science. https://doi.org/10.1111/cts.70244

Vancouver

Fitch R, Mould DR, Conoscenti V, Huang R, Harper D. Phase 1 Study Evaluating the Pharmacokinetics, Dose Proportionality, Bioavailability, and Tolerability of Subcutaneous Levothyroxine Sodium ( XP ‐8121). Clinical and Translational Science. 2025. doi:10.1111/cts.70244

BibTeX
@article{Fitch2025,
  author = {Fitch, Richard and Mould, Diane R and Conoscenti, Valentina and Huang, Robbie and Harper, Dawn},
  title = {Phase 1 Study Evaluating the Pharmacokinetics, Dose Proportionality, Bioavailability, and Tolerability of Subcutaneous Levothyroxine Sodium ( XP ‐8121)},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70244}
}
Kostenlos starten →